100.
Human carbonyl reductase 1 as efficient catalyst for the reduction of glutathionylated aldehydes derived from lipid peroxidation. Rotondo R, Moschini R, Renzone G, Tuccinardi T, Balestri F, Cappiello M, Scaloni A, Mura U, Del-Corso A. Free Radic Biol Med. 2016, 99:323-332.
99.
α-Glucosidase and α-Amylase Inhibitors from Arcytophyllum thymifolium. Milella L, Milazzo S, De Leo M, Vera Saltos M, Faraone I, Tuccinardi T, Lapillo M, De Tommasi N, Braca A. J Nat Prod. 2016, 79(8):2104-12.
98.
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach. Tuccinardi T, Poli G, Corchia I, Granchi C, Lapillo M, Macchia M, Minutolo F, Ortore G, Martinelli A. Molecular Inf. 2016, 35(8-9):434-439.
97.
Pyrazolylbenzo[d]imidazoles as new potent and selective inhibitors of carbonic anhydrase isoforms hCA IX and XII. Kumar S, Ceruso M, Tuccinardi T, Supuran CT, Sharma PK. Bioorg Med Chem. 2016, 24(13):2907-29013.
96.
Cyclic Ketoximes as Estrogen Receptor β Selective Agonists. Granchi C, Lapillo M, Spena CR, Rizzolio F, Tuccinardi T, Martin TA, Carlson KE, Katzenellenbogen JA, Minutolo F. ChemMedChem. 2016, 11(16):1752-61.
95.
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists. Tabrizi MA, Baraldi PG, Ruggiero E, Saponaro G, Baraldi S, Poli G, Tuccinardi T, Ravani A, Vincenzi F, Borea PA, Varani K. Eur J Med Chem. 2016, 113:11-27.
94.
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin’s lymphoma cell models. Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A. Eur J Med Chem. 2016, 111:193-201.
93.
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors. Granchi C, Rizzolio F, Bordoni V, Caligiuri I, Manera C, Macchia M, Minutolo F, Martinelli A, Giordano A, Tuccinardi T. J Enzyme Inhib Med Chem. 2016, 31(1):137-146.
92.
Salicylketoximes That Target Glucose Transporter 1 Restrict Energy Supply to Lung Cancer Cells. Granchi C, Qian Y, Yeon Lee H, Paterni I, Pasero C, Iegre J, Carlson KE, Tuccinardi T, Chen X, Katzenellenbogen JA, Hergenrother PJ, Minutolo FM. ChemMedChem. 2015, 10(11):1892-1900.
91.
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in vivo Antiangiogenic Activity. Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A. J Med Chem. 2015, 58(18):7224-7240.
90.
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands. Tuccinardi T, Poli G, dell’Agnello M, Granchi C, Minutolo F, Martinelli A. J Enzyme Inhib Med Chem. 2015, 30(4):662-670.
89.
Probing the ‘bipolar’ nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Krasavin M, Korsakov M, Dorogov M, Tuccinardi T, Dedeoglu N, Supuran CT. Eur J Med Chem. 2015, 101:334-347.
88.
The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. Nassini R, Fusi C, Materazzi S, Coppi E, Tuccinardi T, Marone IM, De Logu F, Preti D, Tonello R, Chiarugi A, Patacchini R, Geppetti P, Benemei S. Br J Pharmacol. 2015, 172(13):3397-3411.
87.
Studies on the ATP binding site of Fyn kinase for the identification of new inhibitors and their evaluation as potential agents against tauopathies and tumors. Tintori C, La Sala G, Vignaroli G, Botta L, Fallacara AL, Falchi F, Radi M, Zamperini C, Dreassi E, Dello Iacono L, Orioli D, Biamonti G, Garbelli M, Lossani A, Gasparrini F, Tuccinardi T, Laurenzana I, Angelucci A, Maga G, Schenone S, Brullo C, Musumeci F, Desogus A, Crespan E, Botta M. J Med Chem. 2015 58(11):4590-4609.
85.
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH). Tabrizi MA, Baraldi PG, Ruggiero E, Saponaro G, Baraldi S, Romagnoli R, Martinelli A, Tuccinardi T. Eur J Med Chem. 2015, 97:289-305.
84.
Development and Validation of a Docking-Based Virtual Screening Platform for the Identification of New Lactate Dehydrogenase Inhibitors. Granchi C, Capecchi A, Del Frate G, Martinelli A, Macchia M, Minutolo F, Tuccinardi T. Molecules. 2015, 20(5):8772-8790.
83.
Application of a FLAP-Consensus Docking Mixed Strategy for the Identification of New FAAH Inhibitors. Poli G, Giuntini N, Martinelli A, Tuccinardi T. J Chem Inf Model. 2015, 55(3):667-675.
82.
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents. Di BussoloV, Calvaresi EC, Granchi C, Del Bino L, Frau I, Dasso Lang MC, Tuccinardi T, Macchia M, Martinelli A, Hergenrother PJ, Minutolo F. RSC Adv. 2015, 5(26):19944-19954.
81.
Highly selective salicylketoxime-based estrogen receptor beta agonists display antiproliferative activities in a glioma model. Paterni I, Bertini S, Granchi C, Tuccinardi T, Macchia M, Martinelli A, Caligiuri I, Toffoli G, Rizzolio F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Minutolo F. J Med Chem. 2015, 58(3):1184–1194.
80.
Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins. Enyedy EA, Dömötör O, Bali K, Hetényi A, Tuccinardi T, Keppler BK. J Biol Inorg Chem. 2015, 20(1):77-88.
79.
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1. Fusi C, Materazzi S, Benemei S, Coppi E, Trevisan G, Marone I, Minocci D, De Logu F, Tuccinardi T, Di Tommaso M, Susini T, Moneti G, Pieraccini G, Geppetti P, Nassini R. Nature Communications 2014 , 5:5736.
78.
Extensive Consensus Docking Evaluation for Ligand Pose Prediction and Virtual Screening Studies. Tuccinardi T, Poli G, Romboli V, Giordano A, Martinelli A. J Chem Inf Model. 2014, 54(10):2980-2986.
77.
Computational approaches for the identification and optimization of Src family kinases inhibitors. Poli G, Martinelli A, Tuccinardi T. Curr Med Chem. 2014, 21(28):3281-3293.
76.
Identification and characterization of a new reversible MAGL inhibitor. Tuccinardi T, Granchi C, Rizzolio F, Caligiuri I, Battistello V, Toffoli G, Minutolo F, Macchia M, Martinelli A. Bioorg Med Chem. 2014, 22(13):3285-3291.
75.
Targeting Toxic RNAs that Cause Myotonic Dystrophy Type 1 (DM1) with a Bisamidinium Inhibitor. Wong CH, Nguyen L, Peh J, Luu LM, Sanchez JS, Richardson SL, Tuccinardi T, Tsoi H, Chan WY, Chan HY, Baranger AM, Hergenrother PJ, Zimmerman SC. J Am Chem Soc. 2014, 136(17):6355-6361.
74.
Study of the binding interaction between fluorinated Matrix Metalloproteinase inhibitors and Human Serum Albumin. Digilio G, Tuccinardi T, Casalini F, Cassino C, Dias DM, Geraldes CFGC, Catanzaro V, Maiocchi A, Rossello A. Eur J Med Chem. 2014, 79:13-23.
73.
Interaction of anticancer reduced Schiff base coumarin derivatives with human serum albumin investigated by fluorescence quenching and molecular modeling. Dömötör O, Tuccinardi T, Karcz D, Walsh M, Creaven BS, Enyedy E. Bioorg Chem. 2014, 52:16-23.
72.
Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives. Malfitano AM, Laezza C, Saccomanni G, Tuccinardi T, Manera C, Martinelli A, Ciaglia E, Pisanti S, Vitale M, Gazzerro P, Bifulco M. J Neuroimmune Pharmacol. 2013, 8(5):1077-1086.
71.
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. Tuccinardi T, Granchi C, Iegre J, Paterni I, Bertini S, Macchia M, Martinelli A, Qian Y, Chen X, Minutolo F. Bioorg Med Chem. Lett. 2013, 23(24):6923-6927.
70.
Dual targeting of the warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. Calvaresi EC, Granchi C, Tuccinardi T, Di Bussolo V, Huigens III RW, Lee HY, Palchaudhuri R, Macchia M, Martinelli A, Minutolo F, Hergenrother PJ. Chembiochem. 2013, 14(17):2263-2267.
69.
Identification of new FYN kinase inhibitors using a FLAP-based approach. Poli G, Tuccinardi T, Rizzolio F, Caligiuri I, Botta L, Granchi C, Ortore G, Minutolo F, Schenone S, Martinelli A. J Chem Inf Model. 2013, 53(10):2538-2547.
68.
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2- carboxylate (NHI) and malonic (Mal) scaffolds. Granchi C, Calvaresi EC, Tuccinardi T, Paterni I, Macchia M, Martinelli A, Hergenrother PJ, Minutolo F. Org Biomol Chem. 2013, 11(38):6588-6596.
67.
Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists. Aghazadeh Tabrizi M, Baraldi PG, Saponaro G, Moorman A, Romagnoli R, Preti D, Baraldi S, Ruggiero E, Tintori C, Tuccinardi T, Vincenzi F, Borea PA, Varani K. J Med Chem. 2013, 56(11):4482-4496.
66.
Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis. Malfitano AM, Laezza C, D’Alessandro A, Procaccini C, Saccomanni G, Tuccinardi T, Manera C, Macchia M, Matarese G, Gazzerro P, Bifulco M. PLoS One. 2013, 8(5):e62511.
65.
Salicylaldoxime derivatives as new leads for the development of Carbonic Anhydrase inhibitors. Tuccinardi T, Bertini S, Granchi C, Ortore G, Macchia M, Minutolo F, Martinelli A, Supuran CT. Bioorg Med Chem. 2013, 21(6):1511-1515.
64.
Investigating the binding mode of an inhibitor of the MBNL1·RNA complex in myotonic dystrophy type 1 (DM1) leads to the unexpected discovery of a DNA-selective binder. Wong CH, Richardson SL, Ho YJ, Lucas AM, Tuccinardi T, Baranger AM, Zimmerman SC. Chembiochem. 2012, 13(17):2505-2509.
63.
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold. Manera C, Saccomanni G, Malfitano AM, Bertini S, Castelli F, Laezza C, Ligresti A, Lucchesi V, Tuccinardi T, Rizzolio F, Bifulco M, Di Marzo V, Giordano A, Macchia M, Martinelli A. Eur J Med Chem. 2012, 52:284-294.
62.
Computational Studies on Translocator Protein (tspo) and its Ligands. Ortore G, Tuccinardi T, Martinelli A. Curr Top Med Chem. 2012, 12(4):352-359.
61.
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases. Marques SM, Tuccinardi T, Nuti E, Santamaria S, André V, Rossello A, Martinelli A, Santos MA. J Med Chem. 2011, 54(24):8289–8298.
60.
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5. Granchi C, Roy S, Mottinelli M, Nardini E, Campinoti F, Tuccinardi T, Lanza M, Betti L, Giannaccini G, Lucacchini A, Martinelli A, Macchia M, Minutolo F. Bioorg Med Chem Lett. 2011, 21(24):7331-7336.
59.
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Granchi C, Roy S, De Simone A, Salvetti I, Tuccinardi T, Martinelli A, Macchia M, Lanza M, Betti L, Giannaccini G, Lucacchini A, Giovannetti E, Sciarrillo R, Peters GJ, Minutolo F. Eur J Med Chem. 2011, 46(11):5398-5407.
58.
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5). Granchi C, Roy S, Del Fiandra C, Tuccinardi T, Lanza M, Betti L, Giannaccini G, Lucacchini A, Martinelli A, Macchia M, Minutolo F. MedChemComm. 2011, 2(7), 638-643.
57.
Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: a combined spectroscopic and separation approach with molecular modeling studies. Enyedy EA, Horváth L, Hetényi A, Tuccinardi T, Hartinger CG, Keppler BK, Kiss T. Bioorg Med Chem. 2011, 19(14):4202-4210.
56.
Protein Kinase Homology Models: Recent Developments and Results. Tuccinardi T, Martinelli A. Curr Med Chem. 2011;18(19):2848-2853.
55.
Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation. Carrasco MP, Enyedy EA, Krupenko NI, Krupenko SA, Nuti E, Tuccinardi T, Santamaria S, Rossello A, Martinelli A, Santos MA. Med Chem. 2011, 7(4):265-274.
54.
Substituted pyrazolo[3,4-b]pyridines as human A(1) adenosine antagonists: Developments in understanding the receptor stereoselectivity. Tuccinardi T, Zizzari AT, Brullo C, Daniele S, Musumeci F, Schenone S, Trincavelli ML, Martini C, Martinelli A, Giorgi G, Botta M. Org Biomol Chem. 2011, 9(12):4448-4455.
53.
Selective And Potent Agonists For Estrogen Receptor Beta Derived From Molecular Refinements Of Salicylaldoximes. Bertini S, De Cupertinis A, Granchi C, Bargagli B, Tuccinardi T, Martinelli A, Macchia M, Gunther JR, Carlson KE, Katzenellenbogen JA, Minutolo F. Eur J Med Chem. 2011, 46(6):2453-2462.
52.
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells. Granchi C, Roy S, Giacomelli C, Macchia M, Tuccinardi T, Martinelli A, Lanza M, Betti L, Giannaccini G, Lucacchini A, Funel N, León LG, Giovannetti E, Peters GJ, Palchaudhuri R, Calvaresi EC, Hergenrother PJ, Minutolo F. J Med Chem. 2011, 54(6):1599-1612.
51.
Ask the experts: focus on computational chemistry. Bajorath J, Barreca ML, Bender A, Bryce R, Hutter M, Laggner C, Laughton C, Martin Y, Mitchell J, Padova A, Renner S, Selzer PM, Sherman W, Sippl W, Taft C, Tuccinardi T, Vistoli G, Willett P. Future Med Chem. 2011, 3(8):909-21.